Document is current

Article History

Received: 16 February 2025

Accepted: 25 April 2025

First Online: 19 May 2025

Declarations

:

: The study protocol was approved by the Institutional Review Board of Tangdu Hospital (202301-06), Yuncheng Central Hospital (YXLL2024072), and Air Force Hospital of Southern Theatre Command (2024-01). The Ethics Committees waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because this was a retrospective study, and only characteristics and laboratory indicators were collected. We used an anonymized database for all analyses, and all potentially identifying variables were removed. The study involving human participants was conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This trial is a part of ZhuFeng Project (The Clinical Cure Project of Chronic Hepatitis B in China; ClinicalTrials.gov, identifier: NCT04035837) and a part of E-Cure Study (Real World Study of Peginterferon α-2b Treatment for Inactive Chronic Hepatitis B Patients; ClinicalTrials.gov, identifier NCT05182463).

: Not applicable.

: The authors declare no competing interests.